{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:52:39Z","timestamp":1760784759526,"version":"3.44.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Asubio Pharma Co., Ltd."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bcp.2019.113717","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:12:09Z","timestamp":1574104329000},"page":"113717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Phenotypic-screening generates active novel fetal globin-inducers that downregulate Bcl11a in a monkey model"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2233-2789","authenticated-orcid":false,"given":"Tomohiro","family":"Makino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munetada","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsushi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5125-6618","authenticated-orcid":false,"given":"Hideki","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-1959","authenticated-orcid":false,"given":"Tomoyuki","family":"Tsunemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Yamashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2019.113717_b0005","article-title":"Classification of the disorders of hemoglobin","volume":"3","author":"Forget","year":"2013","journal-title":"Cold Spring Harbor Persp. Med."},{"issue":"22","key":"10.1016\/j.bcp.2019.113717_b0010","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2010-01-251348","article-title":"The inherited diseases of hemoglobin are an emerging global health burden","volume":"115","author":"Weatherall","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2019.113717_b0015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/13543784.2015.1012292","article-title":"Prospects for early investigational therapies for sickle cell disease","volume":"24","author":"Conran","year":"2015","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"12","key":"10.1016\/j.bcp.2019.113717_b0020","doi-asserted-by":"crossref","first-page":"939","DOI":"10.7326\/0003-4819-148-12-200806170-00221","article-title":"Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease","volume":"148","author":"Lanzkron","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.113717_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J. Rare Diseases"},{"issue":"7","key":"10.1016\/j.bcp.2019.113717_b0030","article-title":"beta-thalassemia intermedia: a clinical perspective","volume":"2","author":"Musallam","year":"2012","journal-title":"Cold Spring Harbor Persp. Med."},{"issue":"2","key":"10.1016\/j.bcp.2019.113717_b0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000345734","article-title":"Cross-talk between available guidelines for the management of patients with beta-thalassemia major","volume":"130","author":"Musallam","year":"2013","journal-title":"Acta Haematol."},{"issue":"6","key":"10.1016\/j.bcp.2019.113717_b0040","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1542\/peds.2005-0843","article-title":"Changes in the epidemiology of thalassemia in North America: a new minority disease","volume":"116","author":"Vichinsky","year":"2005","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.bcp.2019.113717_b0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3324\/haematol.2009.017228","article-title":"The life of patients with thalassemia major","volume":"95","author":"Borgna-Pignatti","year":"2010","journal-title":"Haematologica"},{"issue":"118","key":"10.1016\/j.bcp.2019.113717_b0050","first-page":"3479","article-title":"How I treat thalassemia","volume":"29","author":"Ea","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2019.113717_b0055","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2009-09-243154","article-title":"Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study","volume":"115","author":"Taher","year":"2010","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bcp.2019.113717_b0060","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/blood-2012-06-292078","article-title":"Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders","volume":"120","author":"Bauer","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2019.113717_b0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trsl.2014.05.002","article-title":"Epigenetic regulation of fetal globin gene expression in adult erythroid cells","volume":"165","author":"Ginder","year":"2015","journal-title":"Transl. Res."},{"issue":"5","key":"10.1016\/j.bcp.2019.113717_b0070","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bjh.15038","article-title":"Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies","volume":"180","author":"Vinjamur","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.bcp.2019.113717_b0075","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2010-11-316893","article-title":"Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities","volume":"117","author":"Wilber","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2019.113717_b0080","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41588-018-0085-0","article-title":"Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding","volume":"50","author":"Martyn","year":"2018","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2019.113717_b0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hoc.2013.11.009","article-title":"Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies","volume":"28","author":"Perrine","year":"2014","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"5","key":"10.1016\/j.bcp.2019.113717_b0090","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00005792-200109000-00007","article-title":"Pharmacologic modulation of fetal hemoglobin","volume":"80","author":"Steinberg","year":"2001","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.bcp.2019.113717_b0095","doi-asserted-by":"crossref","first-page":"xiii-xviii","DOI":"10.1016\/j.hoc.2014.01.001","article-title":"Emerging therapy in hemoglobinopathies: lessons from the past and optimism for the future","volume":"28","author":"Vichinsky","year":"2014","journal-title":"Hematol\/Oncol Clin. North Am."},{"issue":"2","key":"10.1016\/j.bcp.2019.113717_b0100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2004-01-0322","article-title":"Mortality in sickle cell patients on hydroxyurea therapy","volume":"105","author":"Bakanay","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2019.113717_b0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MOH.0b013e32834521dd","article-title":"Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?","volume":"18","author":"McGann","year":"2011","journal-title":"Curr. Opin. Hematol."},{"issue":"6","key":"10.1016\/j.bcp.2019.113717_b0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.bcp.2019.113717_b0115","first-page":"1790","article-title":"Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease","volume":"93","author":"Atweh","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2019.113717_b0120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ecam\/nem139","article-title":"Fetal hemoglobin inducers from the natural world: A novel approach for identification of drugs for the treatment of beta-thalassemia and sickle-cell anemia","volume":"6","author":"Bianchi","year":"2009","journal-title":"Evidence-based Complement. Alter. Med. eCAM"},{"issue":"11","key":"10.1016\/j.bcp.2019.113717_b0125","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/blood-2015-09-667923","article-title":"Pomalidomide reverses gamma-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors","volume":"127","author":"Dulmovits","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2019.113717_b0130","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1182\/blood-2015-02-629972","article-title":"Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR\/gamma-globin looping","volume":"126","author":"Krivega","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2019.113717_b0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199301143280202","article-title":"A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders","volume":"328","author":"Perrine","year":"1993","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2019.113717_b0140","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2141.1994.tb05073.x","article-title":"Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo","volume":"88","author":"Perrine","year":"1994","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.bcp.2019.113717_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2015.04.005","article-title":"RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases gamma-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model","volume":"43","author":"Rivers","year":"2015","journal-title":"Experiment. Hematol."},{"issue":"3","key":"10.1016\/j.bcp.2019.113717_b0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.3101","article-title":"Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction","volume":"19","author":"Shi","year":"2013","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bcp.2019.113717_b0155","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.12304","article-title":"A randomized phase I\/II trial of HQK-1001, an oral fetal globin gene inducer, in beta-thalassaemia intermedia and HbE\/beta-thalassaemia","volume":"161","author":"Fucharoen","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.bcp.2019.113717_b0160","doi-asserted-by":"crossref","first-page":"E255","DOI":"10.1002\/ajh.23533","article-title":"A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease","volume":"88","author":"Kutlar","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.bcp.2019.113717_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002382","article-title":"Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study","volume":"14","author":"Molokie","year":"2017","journal-title":"PLoS Med."},{"issue":"12","key":"10.1016\/j.bcp.2019.113717_b0170","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-10-408021","article-title":"Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia","volume":"121","author":"Musallam","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2019.113717_b0175","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood-2015-09-618553","article-title":"Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease","volume":"127","author":"Telen","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2019.113717_b0180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bj.2015.10.001","article-title":"Current and future alternative therapies for beta-thalassemia major","volume":"39","author":"de Dreuzy","year":"2016","journal-title":"Biomed. J."},{"key":"10.1016\/j.bcp.2019.113717_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.01.006","article-title":"Recent trends in treatment of thalassemia","author":"El-Beshlawy","year":"2019","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcp.2019.113717_b0190","doi-asserted-by":"crossref","unstructured":"V. Ghiaccio, M. Chappell, S. Rivella, L. Breda, Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges, Molecular diagnosis & therapy, 2019.","DOI":"10.1007\/s40291-019-00383-4"},{"issue":"3","key":"10.1016\/j.bcp.2019.113717_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059890","article-title":"Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells","volume":"8","author":"Kurita","year":"2013","journal-title":"PloS one"},{"issue":"1","key":"10.1016\/j.bcp.2019.113717_b0200","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/adt.2009.9996","article-title":"AlphaLISA immunoassay platform- the \u201cno-wash\u201d high-throughput alternative to ELISA","volume":"7","author":"Bielefeld-Sevigny","year":"2009","journal-title":"Assay Drug Dev. Technol."},{"issue":"4","key":"10.1016\/j.bcp.2019.113717_b0205","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2007-01-068635","article-title":"Developmental- and differentiation-specific patterns of human gamma- and beta-globin promoter DNA methylation","volume":"110","author":"Mabaera","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2019.113717_b0210","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.exphem.2008.06.014","article-title":"A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger","volume":"36","author":"Mabaera","year":"2008","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.bcp.2019.113717_b0215","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1172\/JCI32322","article-title":"Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells","volume":"118","author":"Moutouh-de Parseval","year":"2008","journal-title":"J. Clin. Investig."},{"issue":"6765","key":"10.1016\/j.bcp.2019.113717_b0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bcp.2019.113717_b0225","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.bcp.2019.113717_b0230","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.21020","article-title":"Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis","volume":"82","author":"Lavelle","year":"2007","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcp.2019.113717_b0235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1479-5876-8-92","article-title":"S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)","volume":"8","author":"Lavelle","year":"2010","journal-title":"J. Transl. Med."},{"issue":"13","key":"10.1016\/j.bcp.2019.113717_b0240","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/blood-2002-02-0353","article-title":"Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo","volume":"100","author":"Pace","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2019.113717_b0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.bcp.2019.113717_b0250","unstructured":"F.C. Hillman RS, Red cell manual 7ed.1996."},{"issue":"4","key":"10.1016\/j.bcp.2019.113717_b0255","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood.V67.4.1083.1083","article-title":"On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation","volume":"67","author":"Lavelle","year":"1986","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bcp.2019.113717_b0260","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/blood-2016-01-678128","article-title":"Customizing the genome as therapy for the beta-hemoglobinopathies","volume":"127","author":"Canver","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2019.113717_b0265","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1182\/blood-2012-12-472308","article-title":"LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo","volume":"122","author":"Lee","year":"2013","journal-title":"Blood"},{"issue":"6270","key":"10.1016\/j.bcp.2019.113717_b0270","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.aad3312","article-title":"Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin","volume":"351","author":"Masuda","year":"2016","journal-title":"Science"},{"issue":"7259","key":"10.1016\/j.bcp.2019.113717_b0275","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/nature08243","article-title":"Developmental and species-divergent globin switching are driven by BCL11A","volume":"460","author":"Sankaran","year":"2009","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bcp.2019.113717_b0280","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1101\/gad.1897310","article-title":"Transcriptional silencing of gamma-globin by BCL11A involves long-range interactions and cooperation with SOX6","volume":"24","author":"Xu","year":"2010","journal-title":"Genes Dev."},{"issue":"9","key":"10.1016\/j.bcp.2019.113717_b0285","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ng.637","article-title":"KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching","volume":"42","author":"Zhou","year":"2010","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.bcp.2019.113717_b0290","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and challenges in phenotypic drug discovery: an industry perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.bcp.2019.113717_b0295","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd4366","article-title":"Phenotypic screening in cancer drug discovery - past, present and future","volume":"13","author":"Moffat","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bcp.2019.113717_b0300","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.bcp.2019.113717_b0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144660","article-title":"Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice","volume":"10","author":"Boosalis","year":"2015","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.bcp.2019.113717_b0310","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/1087057109333975","article-title":"A novel high-throughput screening assay for sickle cell disease drug discovery","volume":"14","author":"Pais","year":"2009","journal-title":"J. Biomol. Screen."},{"issue":"9","key":"10.1016\/j.bcp.2019.113717_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107006","article-title":"A cell-based high-throughput screen for novel chemical inducers of fetal hemoglobin for treatment of hemoglobinopathies","volume":"9","author":"Peterson","year":"2014","journal-title":"PloS One"},{"issue":"1\u20133","key":"10.1016\/j.bcp.2019.113717_b0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.bcp.2019.113717_b0325","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ng2108","article-title":"A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15","volume":"39","author":"Menzel","year":"2007","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.bcp.2019.113717_b0330","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.0711566105","article-title":"Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia","volume":"105","author":"Uda","year":"2008","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.bcp.2019.113717_b0335","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood-2015-04-638528","article-title":"2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment","volume":"126","author":"Funnell","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2019.113717_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.016","article-title":"Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2019.113717_b0345","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2012-07-443986","article-title":"Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells","volume":"121","author":"Macari","year":"2013","journal-title":"Blood"},{"issue":"7023","key":"10.1016\/j.bcp.2019.113717_b0350","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature03203","article-title":"Role of the proto-oncogene Pokemon in cellular transformation and ARF repression","volume":"433","author":"Maeda","year":"2005","journal-title":"Nature"},{"issue":"R2","key":"10.1016\/j.bcp.2019.113717_b0355","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1093\/hmg\/ddw170","article-title":"Hemoglobin genetics: recent contributions of GWAS and gene editing","volume":"25","author":"Smith","year":"2016","journal-title":"Hum. Mol. Genet."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219304162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219304162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:11:21Z","timestamp":1757769081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219304162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":71,"alternative-id":["S0006295219304162"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113717","relation":{},"ISSN":["0006-2952"],"issn-type":[{"type":"print","value":"0006-2952"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotypic-screening generates active novel fetal globin-inducers that downregulate Bcl11a in a monkey model","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113717"}}